Evidence map›Paper›PMID 42479115›Full record

ArticleChinese journal of integrative medicine2026

Hyperoside Exerts Therapeutic Effects on Parkinson's Disease by Mitigating Oxidative Stress through Activation of Nrf2/HO-1 Pathway.

Si-Xiang Niu, Li-Shan Fan, Jing-Yi Cheng, Lei Xu, Li-Xia Yang, Sheng-Nan Xiao, Rui-Rui Sun, Shao-Chen Qin, Bao-Guo Xiao, Hui-Jie Fan and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Si-Xiang NiuThe Key Research Laboratory for Prevention and Treatment of Parkinson's Disease by Integrated Traditional Chinese and Western Medicine of Administration of Traditional Chinese Medicine in Shanxi Province/Research Center of Neurobiology, Shanxi University of Chinese Medicine, Jinzhong, Shanxi Province, 030619, China.
Li-Shan FanThe Key Research Laboratory for Prevention and Treatment of Parkinson's Disease by Integrated Traditional Chinese and Western Medicine of Administration of Traditional Chinese Medicine in Shanxi Province/Research Center of Neurobiology, Shanxi University of Chinese Medicine, Jinzhong, Shanxi Province, 030619, China.
Jing-Yi ChengThe Key Research Laboratory for Prevention and Treatment of Parkinson's Disease by Integrated Traditional Chinese and Western Medicine of Administration of Traditional Chinese Medicine in Shanxi Province/Research Center of Neurobiology, Shanxi University of Chinese Medicine, Jinzhong, Shanxi Province, 030619, China.
Lei XuThe Key Research Laboratory for Prevention and Treatment of Parkinson's Disease by Integrated Traditional Chinese and Western Medicine of Administration of Traditional Chinese Medicine in Shanxi Province/Research Center of Neurobiology, Shanxi University of Chinese Medicine, Jinzhong, Shanxi Province, 030619, China.
Li-Xia YangThe Key Research Laboratory for Prevention and Treatment of Parkinson's Disease by Integrated Traditional Chinese and Western Medicine of Administration of Traditional Chinese Medicine in Shanxi Province/Research Center of Neurobiology, Shanxi University of Chinese Medicine, Jinzhong, Shanxi Province, 030619, China.
Sheng-Nan XiaoThe Key Research Laboratory for Prevention and Treatment of Parkinson's Disease by Integrated Traditional Chinese and Western Medicine of Administration of Traditional Chinese Medicine in Shanxi Province/Research Center of Neurobiology, Shanxi University of Chinese Medicine, Jinzhong, Shanxi Province, 030619, China.
Rui-Rui SunThe Key Research Laboratory for Prevention and Treatment of Parkinson's Disease by Integrated Traditional Chinese and Western Medicine of Administration of Traditional Chinese Medicine in Shanxi Province/Research Center of Neurobiology, Shanxi University of Chinese Medicine, Jinzhong, Shanxi Province, 030619, China.
Shao-Chen QinDepartment of Needs/International Medical, Shanxi Provincial People's Hospital, Special, Taiyuan, 030024, China.
Bao-Guo XiaoInstitutes of Brain Science and State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, 200433, China.
Hui-Jie FanThe Key Research Laboratory for Prevention and Treatment of Parkinson's Disease by Integrated Traditional Chinese and Western Medicine of Administration of Traditional Chinese Medicine in Shanxi Province/Research Center of Neurobiology, Shanxi University of Chinese Medicine, Jinzhong, Shanxi Province, 030619, China.
Zhi ChaiThe Key Research Laboratory for Prevention and Treatment of Parkinson's Disease by Integrated Traditional Chinese and Western Medicine of Administration of Traditional Chinese Medicine in Shanxi Province/Research Center of Neurobiology, Shanxi University of Chinese Medicine, Jinzhong, Shanxi Province, 030619, China. chaizhi008@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate whether hyperoside (HYP), the main active ingredients of Wuzi Yanzong Pill, can reduce oxidative stress (OS) damage and treat Parkinson's disease (PD) by activating the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) pathway.

methodsMPTP-induced PD mouse model was established and animals were divided into 5 groups by random number table method: control group, MPTP group (15, 20, and 30 mg/kg on days 1, 2 and 3-7, respectively), and MPTP+HYP low-, medium-, and high-dose groups (25, 50, and 100 mg·kg

resultsIn animal experiments, HYP intervention improved motor abilities, increased TH, Nrf2, HO-1, and Bcl-2 expressions, and reduced Bax expression compared to the MPTP group (P<0.05 or P<0.01). It also elevated GSH, GSH-Px, SOD, and CAT levels, decreased MDA, and reduced neuronal apoptosis (P<0.05 or P<0.01). Molecular docking and dynamics showed HYP binds effectively to Nrf2. Multivariate analysis revealed a strong correlation between HYP's therapeutic effect on PD and OS via the Nrf2/HO-1 pathway. In cell experiments, ML385 inhibited Nrf2/HO-1 activation by HYP (P<0.05 or P<0.01), diminishing its effect on OS and apoptosis.

conclusionHYP can reduce OS and apoptosis by activating the Nrf2/HO-1 pathway, thereby exerting a therapeutic effect in PD.

Indexed as

Chinese medicinehyperosideNrf2/HO-1 pathwayoxidative stressParkinson’s disease

Identifiers

PMID42479115

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.